Christian Schütz
Partner @ b2venture
Saint Gallen, Switzerland
Christian Schütz is a seed investor at b2venture in Saint Gallen focused on Health Care and Medical. Christian Schütz is based out of Saint Gallen, Sankt Gallen and is the Partner of b2venture. Christian Schütz attended the EBS University of Business and Law.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Christian Schütz invests in
Stages Christian Schütz invests in
Countries Christian Schütz invests in
Investment Focus
Industry
- Health Care 2 (22%)
- Medical 1 (11%)
- Consumer 1 (11%)
- Hospital 1 (11%)
- Software 1 (11%)
Stage
- Seed 2 (22%)
- Series A 1 (11%)
- Series B 1 (11%)
- Series C 1 (11%)
- Series D 1 (11%)
Country
- Belgium 1 (11%)
- United States 1 (11%)
- United Kingdom 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NOAT
|
We create tools that kill smoking. | $7M / Seed / Jan 01, 2025 | |
Quanta
|
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $60M / Series E / Nov 18, 2024 | |
|
Quanta
|
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $245M / Series D / Jun 23, 2021 | |
LynxCare
|
LynxCare is an AI-powered Big Data platform. We enable hospitals to mine their legacy data, to improve clinical efficiency and higher the quality of care. | $2M / Jan 29, 2020 | |
|
LynxCare
|
LynxCare is an AI-powered Big Data platform. We enable hospitals to mine their legacy data, to improve clinical efficiency and higher the quality of care. | $2M / Seed / Jan 29, 2020 | |
|
LynxCare
|
LynxCare is an AI-powered Big Data platform. We enable hospitals to mine their legacy data, to improve clinical efficiency and higher the quality of care. | $2M / Seed / Jan 29, 2020 | |
|
Quanta
|
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $49.8M / Series C / Jul 29, 2019 | |
|
Quanta
|
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $35.4M / Series B / Nov 03, 2014 | |
|
Quanta
|
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flowrates of traditional in-centre machines.SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians. | $14.3M / Series A / Nov 01, 2009 |
Co-Investors
Seroba Life Sciences
4 deals together
Wellington Partners
4 deals together
Alchemist Accelerator
3 deals together
HERAN Partners
3 deals together
Glenview Capital Management
2 deals together
NBGI Ventures
2 deals together
About b2venture
B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.
b2venture Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andreas Goeldi
Partner
|
|||
|
Christian Schütz
Partner
|
|||
Florian Schweitzer
Founding Partner
|
|||
Jochen Gutbrod
Partner and Executive Chairman
|
|||
Mathias Ockenfels
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Christian Schütz invest in?
Christian Schütz invests primarily in Health Care, Medical and Consumer startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Christian Schütz last invest?
The most recent investment recorded for Christian Schütz closed in Jan 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
